Bavarian Nordic's COVID shot vanquished by variant vulnerability as phase 3 data reveal flaw

Bavarian Nordic’s vision of ending the COVID-19 vaccine adaptation cycle is over. The Danish drugmaker found its phase 3 trial data support the need for variant-specific vaccines and, because its shot cannot be adapted quickly, has accepted the candidate “no longer represents a commercial opportunity.”